ArticleCancer letters2012

Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Brian J Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.